Plain-English translation of NCT06908694 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether semaglutide, a medication originally developed to help with weight loss and blood sugar control, can safely help men with prostate cancer who are receiving hormone therapy. Hormone therapy for prostate cancer often causes weight gain, high blood pressure, and other heart health problems. Researchers want to see if this medication can help control those side effects while keeping prostate cancer under control.
Men receiving hormone therapy for prostate cancer often experience unwanted weight gain and increased risk of heart disease. Doctors need to know whether this medication—which has helped people lose weight in other settings—can safely address these problems in prostate cancer patients without interfering with their cancer treatment.
You would receive weekly injections of the medication under your skin, starting with a low dose that gradually increases over the first four months to find the best dose for you. You would have visits at the start, at one month by phone, at three months in person, at six months, and at twelve months when the trial ends. At these visits, the research team will check your weight, blood pressure, blood sugar, cholesterol, and prostate-specific antigen (PSA) levels to see how the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Canada
Phase
Post-approval monitoring
Sponsor
Hamilton Health Sciences Corporation
Collaborators
McMaster University
Enrollment target
~20 participants
Started
July 2025
Primary completion
October 2027
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in September 2026.